Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scot C Remick

Showing results (61-70 of 93) with videos related to

Pageof 10
Sort By:
Cancer Detection and Prevention|April 15, 2005
Capacity building for the clinical investigation of AIDS malignancy in East AfricaJackson Orem, Mwanda W Otieno, Cecily Banura, et al.
Plos One|January 28, 2014
Developing clinical strength-of-evidence approach to define HIV-associated malignancies for cancer registration in KenyaAnne Korir, Nathan Mauti, Pamela Moats, et al.
Frontiers in Oncology|June 1, 2012
Preliminary clinical and pharmacologic investigation of photodynamic therapy with the silicon phthalocyanine photosensitizer pc 4 for primary or metastatic cutaneous cancersTimothy James Kinsella, Elma D Baron, Valdir C Colussi, et al.
Archives of Dermatology|January 18, 2012
Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides typeNarin Apisarnthanarax, Gary S Wood, Seth R Stevens, et al.
JCO Global Oncology|July 8, 2020
Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 StudyRobert M Strother, Satish Gopal, Meg Wirth, et al.
Seminars in Oncology|October 3, 2003
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working GroupJames H Doroshow, Timothy W Synold, David Gandara, et al.
Cancer Research|June 18, 2002
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancerAfshin Dowlati, Kelly Robertson, Matthew Cooney, et al.
Plos One|May 26, 2010
HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinomaJing Jie Yu, Pingfu Fu, John J Pink, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2011
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumorsAlejandro D Ricart, Edward A Ashton, Matthew M Cooney, et al.
Seminars in Oncology|October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Pageof 10

Showing results (61-70 of 93) with videos related to

Sort By:
Pageof 10
Cancer Detection and Prevention|April 15, 2005
Capacity building for the clinical investigation of AIDS malignancy in East AfricaJackson Orem, Mwanda W Otieno, Cecily Banura, et al.
Plos One|January 28, 2014
Developing clinical strength-of-evidence approach to define HIV-associated malignancies for cancer registration in KenyaAnne Korir, Nathan Mauti, Pamela Moats, et al.
Frontiers in Oncology|June 1, 2012
Preliminary clinical and pharmacologic investigation of photodynamic therapy with the silicon phthalocyanine photosensitizer pc 4 for primary or metastatic cutaneous cancersTimothy James Kinsella, Elma D Baron, Valdir C Colussi, et al.
Archives of Dermatology|January 18, 2012
Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides typeNarin Apisarnthanarax, Gary S Wood, Seth R Stevens, et al.
JCO Global Oncology|July 8, 2020
Challenges of HIV Lymphoma Clinical Trials in Africa: Lessons From the AIDS Malignancy Consortium 068 StudyRobert M Strother, Satish Gopal, Meg Wirth, et al.
Seminars in Oncology|October 3, 2003
Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working GroupJames H Doroshow, Timothy W Synold, David Gandara, et al.
Cancer Research|June 18, 2002
A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancerAfshin Dowlati, Kelly Robertson, Matthew Cooney, et al.
Plos One|May 26, 2010
HPV infection and EGFR activation/alteration in HIV-infected East African patients with conjunctival carcinomaJing Jie Yu, Pingfu Fu, John J Pink, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2011
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumorsAlejandro D Ricart, Edward A Ashton, Matthew M Cooney, et al.
Seminars in Oncology|October 3, 2003
Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working groupChris H Takimoto, Scot C Remick, Sunil Sharma, et al.
Pageof 10